TY - JOUR
T1 - Enzymes and related proteins as cancer biomarkers
T2 - A proteomic approach
AU - Liang, Shu Ling
AU - Chan, Daniel W.
N1 - Funding Information:
Support in part by grants from the NIH/NCI Early Detection Research Network (EDRN) and the Specialized Programs of Research Excellence (SPORE) in prostate and ovarian cancer is gratefully acknowledged.
PY - 2007/5/2
Y1 - 2007/5/2
N2 - Background: The discovery of cancer biomarkers has become a major focus of cancer research, which holds promising future for early detection, diagnosis, monitoring disease recurrence and therapeutic treatment efficacy to improve long-term survival of cancer patients. Most of the functional information of the cancer-associated genes resides in the proteome. Since cancer is a complex disease, it might require a panel of multiple biomarkers in order to achieve sufficient clinical efficacy. Methods: Serum/plasma is the most accessible biological specimen collected from patients. Therefore, serum proteomic diagnostics would be the most promising new test for cancer. With the advent of new and improved proteomic technologies, such as protein chips and mass spectrometry coupled with advanced bioinformatic tools, it is possible to develop potential cancer biomarkers. However, specimen collection, handling, study design and data analysis are essential components for successful biomarker discovery and validation. Multi-center case control study should be conducted with extensive clinical validation to minimize the impact of possible confounding variables (non-biological). Conclusions: Enzymes and related proteins, such as inhibitors, are promising candidates for cancer diagnostics.
AB - Background: The discovery of cancer biomarkers has become a major focus of cancer research, which holds promising future for early detection, diagnosis, monitoring disease recurrence and therapeutic treatment efficacy to improve long-term survival of cancer patients. Most of the functional information of the cancer-associated genes resides in the proteome. Since cancer is a complex disease, it might require a panel of multiple biomarkers in order to achieve sufficient clinical efficacy. Methods: Serum/plasma is the most accessible biological specimen collected from patients. Therefore, serum proteomic diagnostics would be the most promising new test for cancer. With the advent of new and improved proteomic technologies, such as protein chips and mass spectrometry coupled with advanced bioinformatic tools, it is possible to develop potential cancer biomarkers. However, specimen collection, handling, study design and data analysis are essential components for successful biomarker discovery and validation. Multi-center case control study should be conducted with extensive clinical validation to minimize the impact of possible confounding variables (non-biological). Conclusions: Enzymes and related proteins, such as inhibitors, are promising candidates for cancer diagnostics.
KW - Cancer biomarkers
KW - Clinical proteomics
KW - Mass spectrometry
KW - Prostate specific antigen
UR - http://www.scopus.com/inward/record.url?scp=34248217668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34248217668&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2007.02.017
DO - 10.1016/j.cca.2007.02.017
M3 - Review article
C2 - 17382922
AN - SCOPUS:34248217668
SN - 0009-8981
VL - 381
SP - 93
EP - 97
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
IS - 1
ER -